Abstract
7579Background: Duvelisib (DUV), an oral dual inhibitor of PI3K-d,g, is clinically active in hematologic malignancies, including follicular lymphoma (FL), CLL, and T cell lymphoma (Flinn, 2017). PI...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
